Unlike 223Ra, which targets the bone microenvironment, 177Lu-PSMA-617 delivers therapeutic radiation directly to tumor cells, providing a more precise and mechanistically favorable approach [48]. The gene discussed is FOLH1; the disease is neoplasm.